Dear Providers:

May 22, 2013

BENZODIAZEPINES AND BARBITURATES TO BE COVERED BY MEDICARE PART D

Per Section 175 of the Medicare Improvement for Patients and Providers Act of 2008 (MIPPA) amended section 1860D-2(e)(2)(A) of the Act, barbiturates “used in the treatment of epilepsy, cancer, or a chronic mental health disorder” and benzodiazepines will be included in Part D drug coverage effective as of January 1, 2013.

Therefore, effective May 15, 2013, all claims for benzodiazepines and barbiturates for Wyoming Medicaid clients that are also covered by a Medicare Part D plan will need to be billed to the client’s Medicare Part D plan. The only exception to this would be for claims for barbiturates that are not being used to treat epilepsy, cancer, or a chronic mental health disorder, and those claims will still be covered by Wyoming Medicaid.

MISCELLANEOUS

- Effective 5/15/13, all sedative hypnotic/insomnia agents will require a prior authorization for all patients under 18 years of age.

- Eliquis is a preferred agent with a diagnosis of non-valvular atrial fibrillation and relative contraindication to warfarin for approval.

- Juxtapid and Kynamro require prior authorization and will only be approved with the diagnosis of homozygous familial hypercholesterolemia.

- Vascepa is a non-preferred agent requiring a trial and failure of a preferred agent (fenofibrate, gemfibrozil, Tricor) greater than or equal to a 90 day supply in the last 12 months prior to approval.

- Xeljanz is a non-preferred agent and will require a diagnosis of rheumatoid arthritis and a 56 day trial and failure of a preferred agent (Enbrel or Humira) prior to approval.

- Gynazole is a non-preferred agent and will require trial and failure of ALL other medications for vulvovaginal candidiasis prior to approval.

- Nesina is a non-preferred DPP-4 Inhibitor and will require a 90 day trial and failure of metformin AND Januvia or Onglyza prior to approval.

- Kazano/Oseni are DPP-4 Inhibitor combination agents and will require a 90 day trial and failure of metformin AND Janumet, Juvisync, or Kombiglyze prior to approval.
NEW NON-PREFERRED ANTIDEPRESSANT CRITERIA

- Aplenzin and Forfivo XL – will now require two 6 week trials of the preferred antidepressants, one of which must be a 6 week trial of bupropion SR/ER/XL.

- Viibryd – will now require two 6 week trials of the preferred antidepressants, one of which must be a 6 week trial of either citalopram, escitalopram, fluoxetine, paroxetine IR/CR, or sertraline.

- Cymbalta and Pristiq – will now require two 6 week trials of the preferred antidepressants, one of which must be a 6 week trial of venlafaxine ER CAPSULES.

DATE OF DEATH

Per Medicaid guidelines, a provider may not be paid for claims provided after the client’s date of death. Claims billed after the client’s date of death will be subject to subsequent recovery and possible future audit proceedings.

USE OF DISCOUNT CARDS

Medicaid clients who present discount cards at the pharmacy may not use those discount cards in conjunction with their Medicaid benefits. Discount cards cannot be used on any prescriptions that are paid for in whole or in part by any government program. Claims that have been “split-billed” in this fashion are subject to subsequent recovery and possible future audit proceedings.